ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM: Abstract Number: L10

Dazodalibep, a CD40L Antagonist, in a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of Subjects with Sjögren’s Disease Having Unacceptable Symptomatic Burden but Limited Extraglandular Organ Involvement

Late-Breaking Abstract Poster

9:00AM-11:00AM: Abstract Number: 2365

Decoding the Peripheral Immune Landscape of Systemic Sclerosis to Investigate Disease Stages and Interstitial Lung Disease Progression

(2352–2369) Systemic Sclerosis & Related Disorders – Clinical Poster III: Translational Science

9:00AM-11:00AM: Abstract Number: 1986

Deep Immunophenotyping of Osteoarthritis Patients Demonstrates Baseline Alterations in Monocyte Populations in OA, Dendritic Cell Subpopulations Among Radiographic Progressors, and Th17 Cells Among Pain Progressors

(1977–1995) Osteoarthritis – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 1881

Deep Learning Approaches to Rheumatoid Arthritis Severity Prognosis

(1862–1894) Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2335

Defining a Basket Population for ANA+ Arthritis Trials

(2326–2351) SLE – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 2082

Delivery of Rheumatology Education to Internal Medicine Residents in Rwanda: Evaluation of a New Virtual Rheumatology Course Supplemented by On-site Clinical Teaching

(2061–2088) Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1848

Demographic and Clinical Factors Associated with HPV Vaccination in Young Adults with Rheumatic Disease

(1840–1861) Health Services Research Poster III

9:00AM-11:00AM: Abstract Number: 1784

Dendritic Cell-specific TNFR2 Depletion Reduces Psoriatic Arthritis-like Disease in a Mouse Model

(1776–1795) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1837

Depression and Suicide Attempt in Systemic Lupus Erythematosus with and Without Fibromyalgia

(1827–1839) Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 1843

Detection of Clinically Relevant Subgroups in Patients Undergoing Knee Replacement Using Machine Learning

(1840–1861) Health Services Research Poster III

9:00AM-11:00AM: Abstract Number: 2253

Deucravacitinib, an Oral, Allosteric, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis in POETYK PSO-1 and POETYK PSO-2: Effect on Joint Pain and Peripheral Joint Disease vs Placebo and Apremilast

(2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment: SpA Poster III

9:00AM-11:00AM: Abstract Number: 2328

Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial

(2326–2351) SLE – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 2202

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Moderate to Severe Psoriasis: Long-Term Efficacy in Placebo Crossovers

(2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA

9:00AM-11:00AM: Abstract Number: 2026

Developing a Guided Joint Self-Exam for Rheumatoid Arthritis Patients to Use in Telehealth-Delivered Care

(2019–2038) Patient Outcomes, Preferences, & Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 2027

Developing and Implementing a Pilot Educational Intervention to Improve Readiness for Self-Management Among Patients with Rheumatic Diseases in Uganda

(2019–2038) Patient Outcomes, Preferences, & Attitudes Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].